Spots Global Cancer Trial Database for Anlotinib and Irinotecan for Ewing Sarcoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Anlotinib and Irinotecan for Ewing Sarcoma
Official Title: Anlotinib and Irinotecan for Advanced Ewing Sarcoma After Failure of Standard Multimodal Therapy
Study ID: NCT03416517
Conditions
Study Description
Brief Summary: The investigators explored the activity of anlotinib combined with irinotecan in patients with relapsed and metastatic Ewing Sarcoma.
Detailed Description: After standard multimodal therapy, the prognosis of relapsed and metastatic Ewing Sarcoma is dismal and unchanged over the last decades.Thus, the investigators explored the activity of anlotinib combined with irinotecan in patients with relapsed and metastatic Ewing Sarcoma after the failure of first-line chemotherapy with doxorubicin, vincristine, cyclophosphamide, ifosphamide and etoposide.
Eligibility
Minimum Age: 5 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Peking University First Hospital, Beijing, , China
Peking University People's Hospital, Beijing, , China
Peking University Shougang Hospital, Beijing, , China
Peking University Third Hospital, Beijing, , China
People's Liberation Army General Hospital, Beijing, , China
Contact Details
Name: Wei Guo, M.D, Ph.D
Affiliation: Peking University People's Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
